Efficacy and Safety of Half dose Tirofiban in Patients with Acute Coronary Syndrome Undergoing PCI
Abstract：Objective To investigate the values and safety of tirofiban in different dose in patients with acute coronary syndrome (ACS)undergoing percutaneous coronary intervention (PCI).Methods Totally 143 patients suffered from acute coronary syndromes were selected and divided into two groups according to dose (full dose and half dose)of tirofiban.Patients in two groups were given routinely standardized treatment of coronary heart disease and loading dose tirofiban 10μg/kg in 3 min.Then 0.15μg/(kg·min)and 0.075μg/(kg·min)were intravenously infused in 48 h in full dose group and half dose groups,respectively.Based clinical charac-teristics and TIMI blood flow grade after PCI,left ventricular ej ection fraction (LVEF),the level of isoenzyme of creatine kinase MB (CK MB),and major adverse cardiac events rates (MACE)during hospital after PCI were analyzed.Results There was no statisti-cal significance in the clinical data between the two groups.There was no statistical significance in the rate of IRA achieved TIMI3 af-ter operation,the level of CK MB,heart function,and early MACE between two groups.Conclusion Tirofiban was a safe and tolera-ble drug for ACS patients undergoing PCI.The half dose of it did not increase he incidence rate of cardiovascular events.
Keywords：acute coronary syndromepercutaneous coronary interventiontirofibansafety
Publication Date：2014-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 925-927 )